CytomX Therapeutics (CTMX) Return on Capital Employed (2015 - 2026)
CytomX Therapeutics (CTMX) posted Return on Capital Employed of 29.2% for Q1 2026, down 41.39% on a QoQ basis from 20.65% in Q4 2025, and down 8982.0% year-over-year from 0.33% in Q1 2025.
CytomX Therapeutics (CTMX) Return on Capital Employed (2015 - 2026) Analysis & Trends
CytomX Therapeutics' Return on Capital Employed history runs 12 years deep, the most recent figure standing at 29.2% for Q1 2026.
- Quarterly Return on Capital Employed fell 8982.0% year-over-year to 29.2% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29.2% (down 8982.0% YoY) and the FY2025 annual result came in at 25.01%, down 5816.0% from the prior year.
- Return on Capital Employed was 29.2% for Q1 2026 at CytomX Therapeutics, down from 20.65% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 60.62% in Q1 2025 and bottomed at 111.25% in Q4 2022.
- A 5-year average of 18.7% and a median of 20.65% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 9987 bps — and 2026, when it sank 8982 bps.
- CytomX Therapeutics' Return on Capital Employed stood at 111.25% in 2022, then surged by 90 bps to 11.67% in 2023, then surged by 587 bps to 56.83% in 2024, then sank by 136 bps to 20.65% in 2025, then tumbled by 41 bps to 29.2% in 2026.
- Business Quant data shows CTMX's Return on Capital Employed at 29.2% in Q1 2026, 20.65% in Q4 2025, and 18.5% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | -29.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.20% |
| Dec 31, 2025 | -20.65% |
| Sep 30, 2025 | 18.50% |
| Jun 30, 2025 | 44.21% |
| Mar 31, 2025 | 60.62% |
| Dec 31, 2024 | 56.83% |
| Sep 30, 2024 | 22.46% |
| Jun 30, 2024 | 19.67% |
| Mar 31, 2024 | 22.23% |
| Dec 31, 2023 | -11.67% |
| Sep 30, 2023 | -22.50% |
| Jun 30, 2023 | -59.88% |
| Mar 31, 2023 | -77.64% |
| Dec 31, 2022 | -111.25% |
| Sep 30, 2022 | -105.92% |
| Jun 30, 2022 | -69.67% |
| Mar 31, 2022 | -54.05% |
| Dec 31, 2021 | -41.82% |
| Sep 30, 2021 | -32.95% |
| Jun 30, 2021 | -27.76% |